Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

James Cord

Urology Mesa, AZ Medical Doctor

NPI 1376522284 CMS profile 333773

1234 S Power Rd Ste 102, Mesa, AZ 85206

Open in the dashboard

General payments

$4,673

83 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, James Cord of Mesa, AZ is reported in the CMS Open Payments database as having received $4,673 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $678 30
2020 General $2,068 10
2019 General $1,926 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Cord
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to James Cord were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year James Cord Urology median Middle half National median
2019 $1,926 $480 $147–$1,201 $163
2020 $2,068 $246 $87–$645 $114
2021 $678 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Bayer HealthCare Pharmaceuticals Inc. $1,821 2 payments
  2. NeoTract Inc. $1,619 12 payments
  3. Pfizer Inc. $234 24 payments
  4. Clarus Therapeutics Inc. $210 6 payments
  5. Astellas Pharma US Inc $191 7 payments
  6. AbbVie, Inc. $99 5 payments
  7. Allergan Inc. $69 4 payments
  8. Janssen Biotech, Inc. $53 3 payments
  9. Merck Sharp & Dohme Corporation $47 3 payments
  10. C. R. Bard, Inc. & Subsidiaries $37 2 payments
  11. Other $292 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Consulting Fee $1,800 1 payment
  2. Food and Beverage $1,619 76 payments
  3. Travel and Lodging $1,163 3 payments
  4. Education $91 3 payments
Products named General payments · program years 2019–2021
  1. Xofigo $1,800 1 payment
  2. UROLIFT $1,619 12 payments
  3. XTANDI $249 24 payments
  4. JATENZO testosterone replacement therapy $210 6 payments
  5. JATENZO testosterone replacement therapy $210 6 payments
  6. JATENZO testosterone replacement therapy $210 6 payments
  7. MYRBETRIQ $103 5 payments
  8. BOTOX $69 4 payments
  9. LUPRON DEPOT $57 3 payments
  10. ERLEADA $53 3 payments
  11. Other $499 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record